CardioNerds @AHA23: KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension

Published: 15 Nov 2023

  • Views:

    Views Icon 352
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035). 

This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients with mild to moderate hypertension. 394 participants were enrolled in the trial and were randomised to receive either ALN-AGT01 or placebo. At 6 months, placebo participants were randomized to receive one of the initial ALN-AGT01 regimens until the end of the 12-month treatment period. 

The primary endpoint is the change from baseline at three months in 24-hour mean systolic blood pressure (SBP) assessed by ambulatory blood pressure monitoring (ABPM).

Results suggest that single subcutaneous doses of zilbesiran showed clinically significant reductions in 24-hour mean SBP as compared to placebo at 3 months, which was sustained through to month 6. An encouraging safety profile was demonstrated across this period, with low rates of serious or severe adverse events, and mild to moderate drug-related events observed across all zilbesiran regimens. Study of the drug will continue in the ongoing KARDIA-2 phase 2 study.

Recorded on-site at AHA 2023, Philadelphia.

Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.


You must be to comment. If you are not registered, you can register here.